These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 2933583)

  • 1. [Effect of long-term high-dose progesterone (Depo-Provera) therapy on endometrial carcinoma].
    Szarvas Z; Zsolnai B; Gimes G; Hidvégi J
    Morphol Igazsagugyi Orv Sz; 1985 Oct; 25(4):253-60. PubMed ID: 2933583
    [No Abstract]   [Full Text] [Related]  

  • 2. Continuous, high-dose progestogen treatment of endometrial cancer.
    Szarvas Z; Zsolnai B; Gimes G; Hidvégi J
    Gynecol Obstet Invest; 1987; 24(4):262-6. PubMed ID: 2962910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Surface changes in endometrial cancer under the effect of large doses of progestogen (Depo-Provera)].
    Szarvas Z; Zsolnai B
    Morphol Igazsagugyi Orv Sz; 1984 Apr; 24(2):92-9. PubMed ID: 6717452
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of progestogen (Depo-Provera) on annulate lamellae in endometrial carcinoma.
    Szarvas Z; Zsolnai B
    Acta Chir Hung; 1984; 25(4):269-76. PubMed ID: 6240879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cell surface changes after high-dosage progesterone treatment in endometrial carcinoma].
    Szarvas Z; Zsolnai B
    Zentralbl Gynakol; 1984; 106(14):1010-7. PubMed ID: 6239468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Response of estrogen and progesterone receptors to treatment with large doses of progestogen (depo-provera) in endometrial cancer].
    Thurzó L
    Zentralbl Gynakol; 1990; 112(17):1111-5. PubMed ID: 2148245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Estrogen and progesterone receptors in endometrial carcinoma during high-dose progestogen (Depo-Provera) therapy].
    Thurzó L; Sas M; Falkay G
    Orv Hetil; 1986 Oct; 127(43):2613-6. PubMed ID: 2947029
    [No Abstract]   [Full Text] [Related]  

  • 8. Endometrial hyperplasia. Clinico-pathological considerations of a prospective randomised study after abrasio only or high-dose gestagen treatment. Results of 2 years follow-up of 292 patients.
    Lindahl B; Willén R
    Anticancer Res; 1991; 11(1):403-6. PubMed ID: 1826823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Progesterone receptors in endometrial carcinoma and their response to medroxyprogesterone acetate].
    Feng YJ; Zhang XY
    Zhonghua Fu Chan Ke Za Zhi; 1989 May; 24(3):153-5, 189. PubMed ID: 2530067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adjuvant hormone therapy in endometrial carcinoma: medroxyprogesterone acetate versus tamoxifen-medroxyprogesterone acetate sequential therapy].
    Vavra N; Salzer H; Sevelda P; Breitenecker G; Czerwenka K; Kucera H
    Gynakol Rundsch; 1990; 30(3):133-43. PubMed ID: 2147161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of endometrial activity after radiation therapy for cervical carcinoma.
    Barnhill D; Heller P; Dames J; Hoskins W; Gallup D; Park R
    Obstet Gynecol; 1985 Dec; 66(6):805-8. PubMed ID: 2999661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The medroxyprogesterone acetate serum level following various medroxyprogesterone acetate dose schedules in gynecologic oncology].
    Husslein P; Egarter C; Eppel W; Salzer H; Spona J
    Zentralbl Gynakol; 1988; 110(20):1277-82. PubMed ID: 2977043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protecting the endometrium. Opposing the hyperplasia/malignancy potential of ERT.
    Gibbons WE; Thorneycroft IH
    J Reprod Med; 1999 Feb; 44(2 Suppl):203-8. PubMed ID: 11392033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Adjuvant gestagen therapy in stage I endometrial cancer].
    Lahousen M; Pickel H
    Zentralbl Gynakol; 1988; 110(16):1013-7. PubMed ID: 2973195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Conservative organ-preserving measures in precancerous stages of endometrial cancer].
    Dallenbach-Hellweg G
    Gynakologe; 1988 Dec; 21(4):302-7. PubMed ID: 2974824
    [No Abstract]   [Full Text] [Related]  

  • 16. [Progestins in combined treatment of endometrial cancer].
    Voznyĭ EK; Titova VA
    Sov Med; 1990; (9):102-7. PubMed ID: 2148437
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical and histological studies of endometrial carcinoma of the uterus treated with medroxy-progesterone-acetate (author's transl)].
    Ohta M; Takeda A; Ninagawa T; Tomoda Y
    Nihon Gan Chiryo Gakkai Shi; 1980 Dec; 15(7):1098-103. PubMed ID: 6453176
    [No Abstract]   [Full Text] [Related]  

  • 18. A randomized trial of progestogens in the primary treatment of endometrial carcinoma.
    Macdonald RR; Thorogood J; Mason MK
    Br J Obstet Gynaecol; 1988 Feb; 95(2):166-74. PubMed ID: 2964861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Oral high doses of medroxyprogesterone acetate (MPA) in the treatment of advanced phases of breast and endometrial cancer].
    Bernardo-Strada MR; Imparato E; Aspesi G; Pavesi L; Robustelli Della Cuna G
    Minerva Med; 1980 Nov; 71(44):3241-6. PubMed ID: 7454090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormone-resistant endometriosis following total abdominal hysterectomy and bilateral salpingo-oophorectomy: correlation with histology and steroid receptor content.
    Metzger DA; Lessey BA; Soper JT; McCarty KS; Haney AF
    Obstet Gynecol; 1991 Nov; 78(5 Pt 2):946-50. PubMed ID: 1833687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.